We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-3.27%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$312M
AUM Growth
-$40.1M
Cap. Flow
+$21.1M
Cap. Flow %
6.76%
Top 10 Hldgs %
95.68%
Holding
21
New
1
Increased
3
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
HLVX
HilleVax
HLVX
+$21.8M
2
XCUR icon
Exicure
XCUR
+$206K
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$6.03K
4
VRNA
Verona Pharma
VRNA
+$4

Top Sells

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$921K

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.81B
$90.7M 29.04%
4,168,718
– –
SRRA
2
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$72.3M 23.14%
1,314,127
+115
+0% +$6.03K
VERA icon
3
Vera Therapeutics
VERA
$2.3B
$40.3M 12.9%
2,960,231
– –
ACET icon
4
Adicet Bio
ACET
$85.2M
$30.9M 9.89%
132,212
– –
HLVX
5
DELISTED
HilleVax
HLVX
$19.9M 6.38%
+1,838,486
New +$21.8M
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$708M
$12.1M 3.88%
1,435,106
– –
JSPR icon
7
Jasper Therapeutics
JSPR
$21M
$10.6M 3.41%
562,856
– –
VRNA
8
DELISTED
Verona Pharma
VRNA
$10.2M 3.26%
2,457,500
+1
+0% +$4
EFTR
9
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$6.46M 2.07%
192,885
– –
OKUR
10
OnKure Therapeutics
OKUR
$154M
$5.41M 1.73%
207,396
– –
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$3.17M 1.01%
1,201,507
– –
NCNA
12
NuCana
NCNA
$5.49M
$2.42M 0.77%
667
– –
PRTK
13
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2M 0.64%
1,041,131
– –
SIEN
14
DELISTED
Sientra, Inc.
SIEN
$1.39M 0.44%
167,359
-67,624
-29% -$921K
XCUR icon
15
Exicure
XCUR
$10.2M
$594K 0.19%
56,327
+9,814
+21% +$206K
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
$385K 0.12%
131,036
– –
MTEM
17
DELISTED
Molecular Templates, Inc.
MTEM
$182K 0.06%
13,333
– –
OBSV
18
DELISTED
ObsEva SA Ordinary Shares
OBSV
$141K 0.05%
87,999
– –
SYRE icon
19
Spyre Therapeutics
SYRE
$8.54B
$121K 0.04%
9,620
– –
OCGN icon
20
Ocugen
OCGN
$416M
$16K 0.01%
7,111
– –

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q2 2022 Portfolio in Review

As of Q2 2022, Abingworth held 21 positions worth $312M, down 11% from $352M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Abingworth deployed $21.1M of net new capital in Q2 2022, opening 1 new position and adding to 3 existing holdings. Its largest new stake was HilleVax: 1,838,486 shares worth $19.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Sientra, Inc., an estimated $921K trimmed.

  • Abingworth's largest Q2 2022 buy was HilleVax: 1,838,486 shares worth $19.9M.
  • Abingworth added most to Exicure in Q2 2022, an estimated $206K increase.
  • Abingworth's biggest Q2 2022 reduction was Sientra, Inc., cutting an estimated $921K.
  • Abingworth's ten largest holdings make up 96% of its $312M portfolio in Q2 2022.
  • Abingworth opened 1 new position and closed 0 in Q2 2022.
  • Abingworth's portfolio value fell 11% quarter-over-quarter to $312M.

Based on Abingworth's 13F filing for Q2 2022, filed 15 Aug 2022.